T2DM Management Flashcards
(23 cards)
Which SGLT2i have effects on MACE?
-canagliflozin
-empagliflozin
Which GLP-1 RAs have effects on MACE?
-dulaglutide
-liraglutide
-semaglutide
Which GLP-1 RAs have effects on CKD?
-semaglutide
Which GLP-1 RA are best for weight loss?
-semaglutide
-tirzepatide
Which drug do we use for diabetes patients with HF?
SGLT2i
Which drug do we use for diabetes patients with CKD?
SGLT2i or GLP-1 RA with proven CKD benefit-Ozempic (according to AACE, SGLT2i preferred)
According to AACE guidelines, which drugs do we use for diabetes patients with stroke/TIA?
-GLP-1 RA or Pioglitazone
Which drugs do we use for diabetes patients with ASCVD or high risk for ASCVD?
-GLP-1 RA or SGLT2i (according to AACE, GLP-1 preferred)
What was the study population of DCCT?
patients with T1DM
What was the conclusion of DCCT?
more intensive insulin therapy lead to decrease in microvascular complications
What was the study population of UKPDS?
patients with T2DM
What medications were the study population of UKPDS on?
-metformin
-SU
-insulin
What was the conclusion of UKPDS?
more intensive treatment led to decrease in mortality and microvascular complications
What was the study population of the ACCORD trial?
older patients with T2DM
What was the conclusion from the ACCORD trial?
intensive glycemic treatment -higher risk of death associated with:
1. A1C > 8.5
2. history of neuropathy
3. history of aspirin use
What was the study population of the ADVANCE trial?
patients with T2DM
What was the conclusion from the ADVANCE trial?
reduction in micro/macrovascular complications with more intensive treatment
What was the study population of the VADT?
patients with T2DM
What was the conclusion from VADT?
intensive therapy decreased microvascular complications
Which two trials showed CVD benefit?
-DCCT
-UKPDS
Which trial showed decreased mortality?
UKPDS
Which trial showed increased mortality?
ACCORD
